Fig. 2: Activated integrin β₂ is a conformationally selective antigen in AML.

a, Identified cross-linked peptides mapped on to the crystal structure of the integrin α_L/integrin β₂ heterodimer (PDB 5E6R). b, Flow cytometry histogram plot showing expression of total and activated integrin β₂ on AML (top) and B cell lines (bottom; BV-173 and Namalwa). The y axis represents percent count normalized to mode. The gating strategy is shown in Supplementary Information 1a. Data are representative of n = 4 (Nomo1), 2 (THP-1) and 1 (all others) independent experiments. c, Flow cytometry plot showing the absence of active integrin β₂ on CD34⁺ HSPCs from GM-CSF-mobilized peripheral blood. The gating strategy is shown in Supplementary Information 1b. Deidentified human samples were used for this analysis (n = 5 independent donors). d, Representative flow cytometry histogram plots showing the expression of active integrin β₂ on primary AML cells. The y axis represents percent count normalized to mode. The gating strategy is shown in Supplementary Information 1c. Data are representative of n = 10 total deidentified samples. e, Heat map showing inverse expression patterns of ITGB2 against other AML targets in publicly available primary AML RNA-seq data. The color bar represents maximum expression in each row based on normalized read counts. The sample sizes of BEAT³⁷ AML (adult), TARGET³⁸ (pediatric) and TCGA³⁶ were 510, 255 and 150, respectively. f, Aggregated single-cell RNA-seq data showing essentially exclusive expression of ITGB2 in hematopoietic tissue; data were obtained from the Human Protein Atlas³⁹; nTPM, normalized transcripts per million.